drugset / Trial / NCT05048524
Peri-operative SLOG for Localized Pancreatic Cancer
NaSingle-groupOpen-labelTreatment
Summary
1. To evaluate the efficacy of neoadjuvant chemotherapy SLOG in localized pancreatic cancer 2. To evaluate the safety profile in patients with pancreatic cancer who receive neoadjuvant SLOG 3. To collect tumor tissue and peripheral blood samples from the patients for a comprehensive biomarker evaluation
Timeline
- Start
- 2021-09-03
- Primary completion
- 2024-08-24
- Completion
- 2025-08-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gemcitabine | Small molecule | 800 mg/m2 | — |
| Subject | Leucovorin | Small molecule | 30 mg | — |
| Subject | Oxaliplatin | Small molecule | 85 mg/m2 | — |
| Subject | S-1 | Small molecule | 80 mg | Oral |
| Subject | S-1 | Small molecule | 100 mg | Oral |
| Subject | S-1 | Small molecule | 120 mg | Oral |